🔗 Share this article

As America proceeds with sweeping revisions to its immunization schedules, one figure has emerged somewhat surprisingly: Høeg, a US-based sports medicine doctor and public health researcher who initially gained attention by questioning COVID-19 vaccines throughout the global health crisis and has concentrated on alleged fatalities after Covid vaccination in her recent position at the Food and Drug Administration.

Scheduled Shifts to Childhood Vaccine Schedule

Public health authorities planned to announce major changes to the pediatric vaccine schedule recently, bringing the US with Denmark’s vaccine program, it is understood – a substantial departure that would place the US out of alignment with much of the international standard with insufficient data for improved outcomes. This reveal has been delayed until the new year.

Instead of the top vaccines chief, Høeg is set to address the audience at the event. She was just designated interim head of the FDA’s CDER, the fifth person to run the office this year.

A Shift at the Agency

This interim role may indicate a tighter collaboration between the pharmaceutical and biologics centers as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it points to a greater focus upon reevaluating already-approved vaccines at the FDA.

The new acting director has often pushed for ending some pediatric shot schedules in the US to become more similar to Denmark, a nation with comprehensive healthcare and a citizenry approximately the size of the state of Wisconsin.

To date statements, she has continued to focus on vaccines – traditionally the responsibility of Dr. Prasad, head of the FDA’s CBER – rather than drug regulation.

Questions Over Qualifications

Dr. Høeg has no apparent track record in medication creation, regulation or leadership, which has been typical for former directors of the CBER. She has worked at the FDA as a top consultant to the agency head and the vaccine center since March.

“She doesn’t seem to have the requisite experience” for leading the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in running a sizeable institution. She is not an expert in drug approvals.”

Past directors of CBER would “grasp laws and regulations and the underlying principles of drug development”, noted Dr. Janet Woodcock. “Frankly, she doesn’t have the sort of resume that former directors who ran the center have had.”

CDER has an enormous range of responsibilities at the FDA, the former commissioner pointed out.

“Many people just zeroes in on the novel medication approvals, but the off-patent medication office authorizes a multitude of generic medications. There is also a biologic copycat branch, non-prescription drug unit and more, and each of these need to be supervised,” she noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

There is also, a major administrative aspect to the job, which supervises more than 5,000 personnel. “It is a huge administrative position, if you do it right,” the former official concluded.

Official Statement and Contentious Policies

In response to concerns about Dr. Høeg's qualifications and whether this appointment indicates greater collaboration among FDA leaders on immunizations, a representative stated that the “questions stem from incorrect premises”.

“This background is consistent with the responsibilities of her role,” the representative said, pointing to the months Høeg spent advising the agency head on “medication safety and approval science, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg inherits the agency head's new fast-track approval initiative, a controversial rapid drug-approval program that reportedly concerned her predecessors. “By what process are these therapies being chosen for this expedited pathway? Who is making the choices?” Howard asked. “There’s a lot of secrecy occurring at the FDA right now.”

Broadly speaking, he said, “the FDA looks to be trending towards laxer rules of most medications, aside from vaccines.”

Documented History on Vaccines

Regarding vaccines, Høeg has a clearer, if concerning, track record, critics observe. She released a study using unverified volunteer-provided data to estimate the frequency of myocarditis after Covid vaccination. She advised the Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to suggest Covid vaccines are more dangerous than they are.

Included in her “wish list” for the incoming administration encompassed altering regulations for novel immunizations and discontinuing “non-essential” vaccines, she stated post-election on a audio program. At the agency, Dr. Høeg has reportedly suggested excluding young men from obtaining Covid vaccinations.

“She is an all-around ideologue who begins with her preconceived notions and tailors the evidence to retrofit the evidence in a extremely misleading, fraudulent manner,” Howard said.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg joined fellow skeptics, {like|